他莫昔芬联合2年卵巢功能抑制改善绝经前乳腺癌DFS
这项随机III期试验纳入化疗后仍维持绝经前状态或恢复卵巢功能的激素受体阳性乳腺癌患者,比较5年他莫昔芬联合2年卵巢功能抑制(OFS,戈舍瑞林每月一次)与单用他莫昔芬的疗效。
要点
- 化疗后仍绝经前或卵巢功能恢复的雌激素受体阳性乳腺癌患者,他莫昔芬加2年OFS可显著改善DFS。
核心结论
- 在化疗后仍维持绝经前状态或恢复卵巢功能的激素受体阳性乳腺癌患者中,他莫昔芬加用2年OFS较单用他莫昔芬显著改善DFS。
研究设计与样本
- 随机III期试验纳入1483例年龄≤45岁、完成辅助或新辅助化疗后接受根治性手术的雌激素受体阳性绝经前乳腺癌患者。
- 入组后每6个月依据卵泡刺激素水平和阴道出血史评估卵巢功能,确认绝经前状态者随机分为5年他莫昔芬单药组或5年他莫昔芬联合2年OFS(戈舍瑞林每月一次)组。
- 共1293例患者随机分组,1282例纳入分析;DFS定义为从入组至首次事件的时间。
临床怎么用
- 对完成化疗后仍处于绝经前状态或卵巢功能恢复的雌激素受体阳性乳腺癌患者,可考虑在他莫昔芬基础上加用2年戈舍瑞林行卵巢功能抑制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The addition of ovarian function suppression (OFS) for 5 years to tamoxifen (TAM) for treatment of premenopausal patients with breast cancer after completion of chemotherapy has beneficial effects on disease-free survival (DFS). This study evaluated the efficacy of adding 2 years of OFS to TAM in patients with hormone receptor-positive breast cancer who remain in a premenopausal state or resume ovarian function after chemotherapy. PATIENTS AND METHODS: We enrolled 1,483 premenopausal women (age ≤ 45 years) with estrogen receptor-positive breast cancer treated with definitive surgery after completing adjuvant or neoadjuvant chemotherapy. Ovarian function was assessed every 6 months for 2 years since enrollment on the basis of follicular-stimulating hormone levels and vaginal bleeding history. If ovarian function was confirmed to be premenopausal at each visit, the patient was randomly assigned to complete 5 years of TAM alone (TAM-only) group or 5 years of TAM with OFS for 2 years that involved monthly goserelin administration (TAM + OFS) group. DFS was defined from the time of enrollment to the time of the first event. RESULTS: A total of 1,293 patients were randomly assigned, and 1,282 patients were eligible for analysis. The estimated 5-year DFS rate was 91.1% in the TAM + OFS group and 87.5% in the TAM-only group (hazard ratio, 0.69; 95% CI, 0.48 to 0.97; P = .033). The estimated 5-year overall survival rate was 99.4% in the TAM + OFS group and 97.8% in the TAM-only group (hazard ratio, 0.31; 95% CI, 0.10 to 0.94; P = .029). CONCLUSION: The addition of 2 years of OFS to TAM significantly improved DFS compared with TAM alone in patients who remained premenopausal or resumed ovarian function after chemotherapy.
引用
- Kim HA, Lee JW, Nam SJ, et al. Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial. J Clin Oncol. 2019. PMID: 31518174. doi:10.1200/JCO.19.00126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。